化工社化工社 化学情報印刷レポート · 研究参考用
二酢酸マンガン(II)·4水和物
二酢酸マンガン(II)·4水和物 · 酢酸マンガン四水和物 · 酢酸マンガン(II)四水和物 · 酢酸マンガン(Ⅱ)四水和物 · 酢酸マンガン（II）?四水和物 · 酢酸マンガン(Ⅱ),四水和物 · 酢酸マンガン(II)四水和物 PURUM P.A.,≥99.0% (KT) · 酢酸マンガン(II)四水和物, 99.9%
識別子と物理属性
| CAS No. | 6156-78-1 |
|---|---|
| 分子式 | C4H6MnO4 . 4H2O |
| 平均分子量 | 245.09 g/mol |
| 単同位体質量 | 245.00691251 g/mol |
| SMILES | CC(=O)[O-].CC(=O)[O-].O.O.O.O.[Mn+2] |
| InChIKey | CESXSDZNZGSWSP-UHFFFAOYSA-L |
| PubChem CID | 93021 |
| EC No. | 612-176-1 |
| DTXSID | DTXSID00210566 |
| 現地名 | 二酢酸マンガン(II)·4水和物 |
化学・物理的性質
| 極性表面積 | 84.3 |
|---|---|
| 水素結合供与体数 | 4 |
| 水素結合受容体数 | 8 |
| 回転可能結合数 | 0 |
| 重原子数 | 13 |
| 形式電荷 | 0 |
| 複雑度 | 25.5 |
| 物質分類 | Metals -> Organic Acids, Metal Salts |
| 密度 | 1.59 @ 20°C1.589 g/mL at 25 °C(lit.) |
| 融点 | 80 °C>300 °C(lit.) |
| Physical Description | Light red transparent solid[Merck Index] Light pink hygroscopic crystals[Acros Organics MSDS] |
| 蒸気圧 | <1 hPa (25 °C) |
| 貯蔵条件 | Store below +30°C. |
| 溶解度 | 233g/リットル水、メタノール、エタノール、酢酸に可溶。 |
| 外観・状態 | クリスタル |
| 比重 | 1.589 |
| 色 | ピンク |
| pH | 7.0 (50g/l, H2O, 20℃) |
| Merck | 14,5724 |
| BRN | 3730728 |
| InChI | 1S/2C2H4O2.Mn.4H2O/c2*1-2(3)4/h2*1H3,(H,3,4)4*1H2/q+2/p-2 |
| InChIKey | SLMRUTJYVMZEPJ-UHFFFAOYSA-M |
| SMILES | [H]O[H].[H]O[H].[H]O[H].[H]O[H].CC(=O)O[Mn]OC(C)=O |
| CAS データベース | 6156-78-1(CAS DataBase Reference) |
化学的特性
PALE PINK CRYSTALS
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 35.1% (26 of 74) of reports.WarningH315 (63.5%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 74 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Danger |
|---|---|
| 規制情報 | Chemical: Acetic acid, manganese(2+) salt, tetrahydrateAcetic acid, manganese(2+) salt, tetrahydrate: Does not have an individual approval but may be used under an appropriate group standard |
| その他の安全情報 | IMAP assessments - Soluble manganese compounds: Human health tier II assessment |
| 有害性の概要 | An irritantPossible reproductive and fetal toxicant[Acros Organics MSDS] See Manganese(II) acetate. See Manganese and linked occupational diseases. |
| Hazard Classes and Categories | Skin Irrit. 2 (63.5%)Acute toxicity (ingestion) - category 4 |
| 暴露管理・個人防護 | 0.2 [mg/m3], as Mn (inhalable fraction), 0.02 mg/m3, as Mn (respirable fraction)[German Research Foundation (DFG)] |
| Minimum Risk Level | Chronic Inhalation: 0.0003 mg/m3 (L134) |
| Threshold Limit Values (TLV) | 0.02 [mg/m3], as Mn (respirable fraction), 0.1 mg/m3, as Mn (inhalable fraction) |
| Protective Action Criteria (PAC) | 13 [mg/m3]22 [mg/m3]740 [mg/m3] |
| 健康影響 | Manganese mainly affects the nervous system and may cause behavioral changes and other nervous system effects, which include movements that may become slow and clumsy. This combination of symptoms when sufficiently severe is referred to as “manganism”. (L228) |
| 有害作用 | Neurotoxin - Parkinsonism |
| 暴露経路 | Oral (L228)inhalation (L228) |
| 毒性の概要 | Manganese is a cellular toxicant that can impair transport systems, enzyme activities, and receptor functions. It primarily targets the central nervous system, particularily the globus pallidus of the basal ganglia. It is believed that the manganese ion, Mn(II), enhances the autoxidation or turnover of various intracellular catecholamines, leading to increased production of free radicals, reactive oxygen species, and other cytotoxic metabolites, along with a depletion of cellular antioxidant defense mechanisms, leading to oxidative damage and selective destruction of dopaminergic neurons. In addition to dopamine, manganese is thought to perturbations other neurotransmitters, such as GABA and glutamate. In order to produce oxidative damage, manganese must first overwhelm the antioxidant enzyme manganese superoxide dismutase. The neurotoxicity of Mn(II) has also been linked to its ability to substitute for Ca(II) under physiological conditions. It can enter mitochondria via the calcium uniporter and inhibit mitochondrial oxidative phosphorylation. It may also inhibit the efflux of Ca(II), which can result in a loss of mitochondrial membrane integrity. Mn(II) has been shown to inhibit mitochondrial aconitase activity to a significant level, altering amino acid metabolism and cellular iron homeostasis. (L228) |
| Signs and Symptoms | Manganese mainly affects the nervous system and may cause behavioral changes and other nervous system effects, which include movements that may become slow and clumsy. This combination of symptoms when sufficiently severe is referred to as “manganism”. (L228) |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| 水環境危害等級（WGK） | 2 |
| TSCA 収載状態 | Yes |
| RTECS 番号 | AI5775000 |
| 毒性 | LD50 orally in Rabbit: 3730 mg/kg |
| PRTR法 | 1-412 |
| 税関コード | 29152990 |
| 危険文句（R） | 36/37/38 |
| 安衛法 | 特定化学物質障害予防規則:第2類物質 |
| 危険表示 | Xi |
| 安全措置（S） | 26-36 |
| 危険等級 | Aquatic Chronic 3STOT RE 2 Inhalation |
| 貯蔵分類 | 11 - Combustible Solids |
用途
用途
ファインセラミックスの製造原科。
用途
酸化反応触媒、媒染剤。
使用
Manganese(II) acetate tetrahydrate may be used in the sol gel synthesis of doped TiO2 containing different amounts of Mn2+.
一般的な説明
Manganese(II) acetate tetrahydrate is a hydrated salt of manganese. Kinetic studies suggest that its dehydration takes place in two-step reaction involving the loss of two water molecules. Its crystal structure has been investigated by X-ray studies. Its crystals exhibit monoclinic crystal system and space group P21/c.
製法・合成法
純化方法
Crystallise it from water acidified with acetic acid. [Beilstein 2 IV 120.]